Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Polysaccharide Diphtheria Conjugate Vaccine · 1 trial · 2 indications
Groups 1 and 2 received booster vaccination; Groups 3 and 4 received primary vaccination. Serum bactericidal activity for the Menactra® meningococcal serogroups A, C, Y, and W-135 were at pre-vaccination for all Groups, and at 7 days (Groups 1 and 3), and 14 days (Groups 2 and 4) post-vaccination.
| Arm | Type | Description |
|---|---|---|
| Menactra® Group 1 | EXPERIMENTAL | Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 3 and Day 7 after booster vaccination. |
| Menactra® Group 2 | EXPERIMENTAL | Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 5 and Day 14 after booster vaccination. |
| Meningococcal Vaccine-naïve Group 3 | EXPERIMENTAL | Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 3 and Day 7 after Menactra® vaccination. |
| Meningococcal Vaccine-naïve Group 4 | EXPERIMENTAL | Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 5 and Day 14 after Menactra® vaccination. |
| Name | Type | Description |
|---|---|---|
| Polysaccharide Diphtheria Conjugate Vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Subject is healthy, as determined by medical history. * Subject is between the ages of 7 and 15 years (not yet 16 years). * For subjects who participated in Study 603-02, subject previously received one dose of Menactra® vaccine or Menomune®-A/C/Y/W-135 vaccine. * The date of ...
Polysaccharide Diphtheria Conjugate Vaccine is used for meningitis and meningococcal infection. It is an investigational vaccine being developed by Sanofi (SNY) and is currently in Phase 2 clinical development. The vaccine is intended to help prevent these serious infectious diseases.
Sanofi (SNY) is developing Polysaccharide Diphtheria Conjugate Vaccine. The vaccine is currently in Phase 2 clinical development for the prevention of meningitis and meningococcal infection. Sanofi is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.
Polysaccharide Diphtheria Conjugate Vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The vaccine is being studied for use in meningitis and meningococcal infection, with one completed Phase 2 trial.
Polysaccharide Diphtheria Conjugate Vaccine has one completed clinical trial, NCT00258856. This Phase 2 study, titled "Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®," enrolled 234 participants in the United States and evaluated antibody persistence related to meningitis and meningococcal infection.
Polysaccharide Diphtheria Conjugate Vaccine is not the same as Menactra or Menomune. The clinical trial NCT00258856 studied children who previously received Menactra or Menomune to assess antibody persistence, but the vaccine itself is a distinct investigational product being developed by Sanofi for meningitis and meningococcal infection.